L3VLUP
ProSign in

FATE · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

FATEGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • FATE
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterFATEGILD
Q3 20208 holders, $446m25 holders, $14.2bn
Q4 202011 holders, $2.0bn27 holders, $13.4bn
Q1 202110 holders, $2.1bn24 holders, $14.5bn
Q2 202111 holders, $2.1bn18 holders, $14.9bn
Q3 20219 holders, $1.3bn20 holders, $16.4bn
Q4 20217 holders, $971m20 holders, $16.8bn
Q1 20227 holders, $677m28 holders, $13.2bn
Q2 20226 holders, $520m26 holders, $13.6bn
Q3 20227 holders, $494m24 holders, $13.3bn
Q4 20225 holders, $116m32 holders, $21.1bn
Q1 20232 holders, $483k27 holders, $21.8bn
Q2 20232 holders, $4.5m24 holders, $20.7bn
Q3 20233 holders, $4.9m24 holders, $20.0bn
Q4 20232 holders, $10.0m22 holders, $21.5bn
Q1 20245 holders, $51m30 holders, $20.3bn
Q2 20243 holders, $10m28 holders, $18.5bn
Q3 20243 holders, $17m29 holders, $24.2bn
Q4 2024none listed holders, n.a.28 holders, $25.9bn
Q1 20251 holders, $6.2m33 holders, $32.0bn
Q2 2025none listed holders, n.a.27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 2025none listed holders, n.a.25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
FATE

Fate Therapeutics Inc

Holders
0
Reported value
$0
Buyers
18
Sellers
5

Breadth +13 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
26
Reported value
$34.2bn
Buyers
22
Sellers
16

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only FATE (0)

None.

Only GILD (26)

AllianceBernstein LP, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →